

Figure 2

		T1	N1	T2	N2	T3	N3	T4	N4	T5	N5	T6	N6
217	p27	UM	UM	M	M	UM	UM	M	M	M	M	M	M
445	14-3-3	UM	UM			M	M	M	M	M	M		
154	Apaf2					M	M	M	M			M	M
268	BRCA1	UM	M	M	UM	M	M	M	M	M	M	M	M
584	Calc	M	M			M	M	D	M	UM	D		
443	Casp8	M	UM			UM	M	UM	M	M	M		
242	CycD2	M	M			M	M	M	M	M	M	M	UM
367	DAPK	UM	M			M	M	M	M	M	M	M	M
659	E-cadr	UM	M			M	M	UM?	UM?	M	M		
552	EDNRB	UM	UM			UM	M	M	M	M	M	M	M
586	EP300	M	M					M	M				
465	ERa-proximal	UM	UM	M	M	M	M	M	M	M	M	M	M
508	ERa-distal	M	M			M	M	M	M	M	M	M	M
523	Fas	UM	UM			UM	M	M	UM	M	D?	M	M
306	FHIT	M	M			UM	UM	M	UM	M	UM		
286	GPC3	M	M			M	M	M	M	M	M	M	M
288	GR	M	M			UM	M	M	M	M	M	M	
366	GSTP1	UM	UM	M	M	M	M	M	M	M	M	M	M
495	HIC1	M	M			M	M	M	M	M	M	M	M
400	HIN	M	UM	UM	UM	M	M	M	M	M	M	M	M
418	hMLH1					M	UM	M	M	UM	UM	UM	M
237	hMSH2					M	M	M	M			M	M
350	ICAM1	UM	UM			M	M	M	M	M	M	M	M
704	MCJ	UM	M			UM	UM	UM					
440	MCT-1	D	M			UM	UM	M	M	M	M		
650	MDG1	M	UM			UM	UM	UM	UM	D	D		
306	MDR-1	M	M			M	UM	M	UM	M	M	M	
190	MGMT					M	M	M	M			M	M
540	Muc2	UM	M	M	M	M	M	M	M	M	M	M	M
716	Myf	M	M			M	M	UM	UM	M	M	UM	UM
380	p15	M	M			D	UM	UM	UM	D	D	UM	D
229	p16	UM	UM			UM	M	D	D	D	D	D	D
249	p21	UM	M			M	M	UM	UM	M	M	M	UM
471	p57	UM	M			UM	M	M	UM	M		UM	M
337	p73	M	M			UM	M	M	UM	M	M	UM	M
175	Pax5	M	M			M	M	M	M	M	M	M	M
315	PR-1proximal					M	M	UM	M	UM	UM	M	M
485	PR-2distal	M	M			M	M	M	M	M	M		
467	RARb2					M	M	M	M				
329	Rassf1A	M	M	M	M	M	M	M	M	M	M	M	M
359	RB1	M	M			M	M	M	M	M	M	M	M
453	RFC1	M	M			M	M	UM	M	M	UM	M	M
234	RIZ1	M	M			M	M	M	M	M	M	M	M
493	SI00A2	M	M			M	UM	D	M	D	M		
357	SOCs1	M	UM			M	M	M	M	M	M	M	M
395	SRBC	M	M			M	M	M	M	M	M	UM	M
196	SYK	M	M			M	M	M	M	M	M	M	M
290	TBSP*	M	UM			UM	M	M	UM	UM	UM?	M	UM
200	TES**	M	M			M	UM	M	UM	M	M	M	M
355	TMS1	M	M			M	M	M	M	M	M	M	M
384	TRANSE	M	M			M	M	M	M	M	M	M	M
633	uPA											UM	M?
146	VHL	M	M			M	M	M	M	M	M	M	M

Figure 2 continued

217	
445	Negative regulator of breast cancer growth
154	
268	Silencing = increased risk of BC; no meth in normal; meth in diff path
584	
443	Correlates with Rassf1a meth in neuroblastoma
242	Methylation frequent in BC (25%), correlates with higher grade, different in intraductal and invasive
367	Methylation correlates with invasive lobular carcinoma, no p53 overexpression, ER positivity
659	Loss of expression correlates with poor survival and ER status; expressed in inflammatory BC.
552	Potential role in osteoblastic mets
586	histone acetyltransferase
465	Silencing - poor risk factor
508	Silencing - poor risk factor
523	Reduced expression - lower DFS, resistance to Tam; expr in 50% of BC vs 91% of benign lesions
306	Progressive loss in breast cancer
286	Growth inhibitor; lost in breast cancer
288	Expression is higher in higher grade
366	
495	Expression - good prognostic marker
400	Expressed only in normal but not in breast cancer
418	Repair gene
237	Repair gene
350	Expression inhibits growth of breast cancer
704	Repair gene
440	Novel oncogene
650	Silencing increases chance of tumor growth
306	
190	Low expression equals poor survival
540	Expression - less aggressive behavior, lymph node mets, higher grade of DCIS
716	Hypermethylation in higher grade tumors
380	Frequently deleted in cancer
229	Frequently deleted in cancer
249	Expression - in higher grade; no correlation with prognosis
471	Loss - poor prognosis. Maternally expressed; expression - better survival at chemotherapy
337	Overexpression - poor prognosis, higher grade; Reduced expression - tumorigenesis; in mets
175	Inhibition leads to loss of growth control via CD19
315	Expression predicts response to horm therapy
485	Expression predicts response to horm therapy
467	Inhibited in tumors
329	Methylated in breast tumors (43%) and small-cell lung cancer (100%)
359	Loss of expression predicts faster growth of tumor; correlates with no node mets
453	Expression - correlates with resistance to folates
234	Loss of expression - a condition for tumor growth
493	Expression is lost in cancer
357	Inhibitor of Jak/Stat; Jak/Stat regulates differentiation; silencing - very freq in AML; no correlation with outcome
395	Interacts with BRCA-1; methylated in cancer cell lines
196	Reduced expression correlates with metastasis
290	Expression of TBSP - good prognosis in DCIS; reduced metastasis
200	Putative tumor-suppressor, freq methylated
355	Reduced expression correlates with tumor growth and resistance to apoptosis
384	Expression in bone mets, unclear whether in breast cancer cells or not
633	Increased activity correlates with mets
146	Deletions of chromosomal region in breast cancer